Abstract
Long non-coding RNAs (lncRNAs) are functionally versatile molecules that regulate gene expression at all levels of biological organization. RNA modulation, at the moment, has emerged as a powerful therapeutic technique to treat human diseases. Lately, lncRNAs have been acknowledged as key players in human metabolism and, indeed, implicated in the etiology of many common diseases other than cancers, where they can perhaps serve as reliable markers to determine disease status or assess outcomes of an intervention. Here, in this review, we cite examples of such lncRNAs, discuss their mechanistic role in human diseases and their genetic association, quote potential biomarkers found in human blood, summarize the methods for therapeutic targeting lncRNAs and examine the progress of lncRNA based drugs in clinical trials. Thus, we propose that lncRNAs serve as both a biomarker and an effective therapeutic target with promising clinical utility to manage human metabolic diseases.
Keywords: Epigenetics, lncRNAs, RNA therapeutics, type 2 diabetes, obesity, cardiovascular disease, neurological disease, human metabolism.
Current Pharmaceutical Design
Title:Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Volume: 27 Issue: 35
Author(s): Khushdeep Bandesh , Daisy Masih , Nirjhar Bhattacharyya and Dwaipayan Bharadwaj *
Affiliation:
- Systems Genomics Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi-110067,India
Keywords: Epigenetics, lncRNAs, RNA therapeutics, type 2 diabetes, obesity, cardiovascular disease, neurological disease, human metabolism.
Abstract: Long non-coding RNAs (lncRNAs) are functionally versatile molecules that regulate gene expression at all levels of biological organization. RNA modulation, at the moment, has emerged as a powerful therapeutic technique to treat human diseases. Lately, lncRNAs have been acknowledged as key players in human metabolism and, indeed, implicated in the etiology of many common diseases other than cancers, where they can perhaps serve as reliable markers to determine disease status or assess outcomes of an intervention. Here, in this review, we cite examples of such lncRNAs, discuss their mechanistic role in human diseases and their genetic association, quote potential biomarkers found in human blood, summarize the methods for therapeutic targeting lncRNAs and examine the progress of lncRNA based drugs in clinical trials. Thus, we propose that lncRNAs serve as both a biomarker and an effective therapeutic target with promising clinical utility to manage human metabolic diseases.
Export Options
About this article
Cite this article as:
Bandesh Khushdeep , Masih Daisy , Bhattacharyya Nirjhar and Bharadwaj Dwaipayan *, Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases, Current Pharmaceutical Design 2021; 27 (35) . https://dx.doi.org/10.2174/1381612827666210315145254
DOI https://dx.doi.org/10.2174/1381612827666210315145254 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Taurine-Diabetes Interaction: From Involvement to Protection
Current Diabetes Reviews Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design Chymase Inhibitors
Current Pharmaceutical Design Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs
Current Drug Metabolism Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Coronary Microcirculation in Heart Failure with Preserved Systolic Function
Current Pharmaceutical Design Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Proteomic Analysis of Glucose-Induced Cardiac Myoblasts and the Potential Role of mir-92b-5p in Regulating Sarcomere Proteins Under a Hyperglycemic Environment
Protein & Peptide Letters Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs Recent Trends in the Discovery of Small Molecule Blockers of Sodium Channels
Current Medicinal Chemistry Mechanical Circulatory Support for End-Stage Heart Failure in Repaired and Palliated Congenital Heart Disease
Current Cardiology Reviews Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery WITHDRAWN: Hydroxysafflor Yellow A Ameliorates Toll-like Receptor 4-Mediated Septic Cardiomyopathy
Current Drug Delivery Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Improvement in Quality of Life in Old People with Aortic Stenosis after Transcatheter Aortic Valve Implantation
Current Signal Transduction Therapy